We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.32B
AUM Growth
-$616M
Cap. Flow
-$442M
Cap. Flow %
-13.32%
Top 10 Hldgs %
35.56%
Holding
123
New
10
Increased
41
Reduced
28
Closed
11

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$31.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$25.3M
3
GPCR icon
Structure Therapeutics
GPCR
+$24.1M
4
UNH icon
UnitedHealth
UNH
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$14.6M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$99.4M
2
PEN icon
Penumbra
PEN
+$47.9M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$44M
4
BSX icon
Boston Scientific
BSX
+$30.4M
5
IDXX icon
Idexx Laboratories
IDXX
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Staples 1.87%
3 Industrials 0.25%
4 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WST icon
26
West Pharmaceutical
WST
$24.9B
$47.9M 1.44%
145,500
+8,250
+6% +$2.92M
PEN icon
27
Penumbra
PEN
$12.8B
$47.7M 1.44%
265,000
-240,000
-48% -$47.9M
EXAS
28
DELISTED
Exact Sciences
EXAS
$45.7M 1.38%
1,081,500
+21,750
+2% +$1.2M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.93B
$45M 1.36%
1,044,261
-720,244
-41% -$26M
SRPT icon
30
Sarepta Therapeutics
SRPT
$1.77B
$44.9M 1.35%
284,000
-43,600
-13% -$5.6M
IRTC icon
31
iRhythm Holdings
IRTC
$4.2B
$42.8M 1.29%
397,500
+5,250
+1% +$536K
ASND icon
32
Ascendis Pharma A/S
ASND
$16.8B
$39.6M 1.19%
290,000
– –
PODD icon
33
Insulet
PODD
$9.79B
$39.4M 1.18%
195,000
-125,000
-39% -$22.5M
GPCR icon
34
Structure Therapeutics
GPCR
$3.78B
$39.3M 1.18%
999,862
+587,213
+142% +$24.1M
TVTX icon
35
Travere Therapeutics
TVTX
$5.78B
$36.8M 1.11%
4,482,265
+1,057,447
+31% +$7.12M
AZTA icon
36
Azenta
AZTA
$1.48B
$36.6M 1.1%
696,000
+1,250
+0.2% +$66.8K
RVMD icon
37
Revolution Medicines
RVMD
$44B
$36.6M 1.1%
943,195
+19,514
+2% +$729K
KYMR icon
38
Kymera Therapeutics
KYMR
$8.94B
$34.7M 1.05%
1,163,973
-358,265
-24% -$12.4M
MREO
39
Mereo BioPharma
MREO
$47.3M
$33.4M 1.01%
9,283,492
+1,141,383
+14% +$3.7M
WRBY icon
40
Warby Parker
WRBY
$3.27B
$33.4M 1.01%
2,080,000
– –
IMVT icon
41
Immunovant
IMVT
$8.25B
$31.3M 0.94%
1,185,654
+35,531
+3% +$1.01M
ALGN icon
42
Align Technology
ALGN
$12.3B
$30.8M 0.93%
127,500
-92,500
-42% -$25.8M
AKRO
43
DELISTED
Akero Therapeutics
AKRO
$25.2M 0.76%
1,074,261
-225,627
-17% -$4.83M
JNJ icon
44
Johnson & Johnson
JNJ
$625B
$24.8M 0.75%
+170,000
New +$25.3M
LFST icon
45
Lifestance Health
LFST
$4.14B
$23.7M 0.71%
4,827,700
+47,700
+1% +$288K
ZLAB icon
46
Zai Lab
ZLAB
$2.62B
$22.5M 0.68%
1,297,873
+750
+0.1% +$13.2K
PCRX icon
47
Pacira BioSciences
PCRX
$997M
$22.5M 0.68%
785,000
-270,500
-26% -$7.7M
LEGN icon
48
Legend Biotech
LEGN
$4.01B
$22.4M 0.67%
505,786
+6,300
+1% +$291K
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.4B
$22.4M 0.67%
3,619,258
+123,002
+4% +$679K
NVO
50
Novo Nordisk
NVO
$209B
$21.1M 0.63%
147,500
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rock Springs Capital Management held 123 positions worth $3.32B, down 16% from $3.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $442M in Q2 2024, closing 11 positions and reducing 28 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Insmed worth $54.2M.

  • Rock Springs Capital Management's largest Q2 2024 buy was Insmed: 808,356 shares worth $54.2M.
  • Rock Springs Capital Management added most to Structure Therapeutics in Q2 2024, an estimated $24.1M increase.
  • Rock Springs Capital Management's biggest Q2 2024 reduction was Immunocore, cutting an estimated $99.4M.
  • Rock Springs Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $44M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.32B portfolio in Q2 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 11 in Q2 2024.
  • Rock Springs Capital Management's portfolio value fell 16% quarter-over-quarter to $3.32B.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.